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X-linked recessive (only MPS II)
Mode of Inheriteance
Autosomal recessive
MPS patients’ needs/problems
Diagnosis Therapy
Molecular study of Portuguese patients
16 unrelated Portuguese patients; 
15 different mutations;
MPS II
11 Portuguese patients; 
5 novel mutations. 
Frequent mutation: R234C (also in Spanish patients) 
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MPS IIIA and IIIB
Molecular study of Portuguese patients
3 patients; 
2 novel mutations. 
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MPS IIIC
Molecular study of Portuguese patients
Molecular study of Tunisian patients
Next-generation-sequencing (NGS) as an approach for the diagnosis of LSDs
Our current NGS-based workflow gene panel seems to be a valid tool for 
the genetic analysis of the classical LSDs associated genes. 
Molecular study of Portuguese patients
Including MPSs

Available Therapies
Enzyme Replacement Therapy
 Available for 4 MPSs
MPS I, MPS II, MPS IVA and MPS VI
Current limitations
– Cost
– Lifelong dependance
– Ineffective for the CNS manifestations
• ‘Broader’ approaches
i.e. 1 therapy 1 disease
(or even more!)
• ‘Personalized’ approaches
i.e. 1 therapy for each mutation/
type of mutation
“With research, possibilities are limitless”…
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enzyme replacement therapies
more effective
able to cross the BBB
“With research, possibilities are limitless”…
• ‘Broader’ approaches
gene therapy
Clinical trials:
Metachromatic leukodystrophy
“With research, possibilities are limitless”…
• ‘Broader’ approaches
Final goal: brain
How?
“With research, possibilities are limitless”…
Clinical trials:
MPS I 
MPS II
MPS IIIA
MPSIIIB
Better vectors
Modified viruses (non-pathogenic)
- + 
*retrovirusess (RNA)
Lentiviruses
*adenoviruses (DNA)
‘adeno-associated’  viruses (AAV)
intracerebroventricular injections
• ‘Broader’ approaches
Genetic substrate reduction
“With research, possibilities are limitless”…
• ‘Personalized’ approaches
Final goal: 
correction/amellioration of 1 mutation in particular
type of mutations
How?
Molecular chaperones
stabilize mutant proteins
promote their transport into the lysosome
“With research, possibilities are limitless”…
• ‘Personalized’ approaches
Final goal: 
correction/amellioration of 1 mutation in particular
type of mutations
How?
Molecular chaperones
Galafold
TM
(Migalastat; Amicus Therapeutics)
“With research, possibilities are limitless”…
• ‘Personalized’ approaches
Final goal: 
correction/amellioration of 1 mutation in particular
type of mutations
How?
 Correction of splicing mutations


“With research, possibilities are limitless”…
Our work at INSA…
• ‘Broader’ approaches
– gSRT for MPS
• ‘Personalized’ approaches
– correction of splicing mutations in different LSDs
Common denominator:
Genetic-based therapies
RNA-based
‘Easy’ to test at a cellular level – 1st stage
• ‘Broader’ approach
• Targets: genes from the GAGs biosynthetic pathway
gSRT for MucoPoliSacharidoses
• ‘Broader’ approach
• Targets: genes from the GAGs biosynthetic pathway
gSRT for MucoPoliSacharidoses
MPS fibroblasts 
oligonucleotide
(siRNA)
mRNA
• The MPS III example
MPS III A MPS III C MPS III D
gSRT for MucoPoliSacharidoses
MPS fibroblasts 
oligonucleotido
(siRNA)
GAGs
• The MPS III example
gSRT for MucoPoliSacharidoses
gSRT for MucoPolySaccharidosis type III
siRNA
MPS III fibroblasts 
Promising results!
Reasons to keep studying...
• ‘Personalized’ approach
Splicing Therapies for LSD
 The MPS example
 MPS III C  
 Splicing mutations frequent (~20%)
 1 quite frequente in
Portuguese
Spanish patients
Morrocan


good motifs to attempt splicing correction as 
a therapeutic approach!
Matos et al. Orphanet Journal of Rare Diseases, 2014
c.234+1G>A
Splicing Therapies for LSD
 The MPS example
 MPS III C  
Matos et al. Orphanet Journal of Rare Diseases, 2014
HGSNAT gene 
+1

Exon 2 skipping
Splicing Therapies for LSD
 The MPS example
 MPS III C  
Matos et al. Orphanet Journal of Rare Diseases, 2014
Molecule
(U1 snRNAs)
mRNA
MPS IIIC fibroblasts 
4  ≠ oligos
comp. 
1-4
Splicing Therapies for LSD
 The MPS example
 MPS III C  
Matos et al. Orphanet Journal of Rare Diseases, 2014
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Splicing Therapies for LSD
Promising results!
Reasons to keep studying...
• in vivo studies
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• in vivo studies
A look forward…
• Design a proper siRNA delivery strategy 
for therapeutic purposes
A look forward…
 Coupling of specific ligands
to siRNA-carring liposomes
o Transferrin (Tf)
o Rabies virus peptide
derivative (RGV-2r)
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